Mikhail Blagosklonny and His Quest for Longer Life

Dr. Mikhail Blagosklonny has worked in many capacities including as a professor of oncology at the Rosewell Park Cancer Institute in New York. In addition to his teaching, he is an avid researcher who is particularly interested in cancer treatments and anti-aging drugs. His hypothesis is that there is certain cell activity that contributes to both aging and the development of cancer, and that there is a particular drug that can be used to treat both these conditions.

In all of his research, Dr. Blagosklonny seeks therapies that allow for the destruction of disease causing cells, while preventing damage to healthy cells. He is considered an expert in his field and one of the leading advocates of a drug called Rapamycin. Also known by the names Sirolimus and Rapamune, Rapamycin is used to treat transplant rejections and a rare form of lung disease, and serves as a coating for coronary stents. If Dr. Blagosklonny has his way, the treatment of cancer will be added to its many uses.

The reason that Rapamycin is becoming the drug of choice is that it has all the properties of other drugs that boost the immune system, but has far less adverse reactions. Research has shown that it enhances the body’s ability to fight tumors and reduces the regrowth of harmful cells, particularly in transplant patients. Preliminary tests have also shown an immune system rejuvenation in the elderly and a greater tendency to combat diseases such as influenza and tuberculosis. Obviously, Rapamycin has enormous potential and research continues to more clearly define its effectiveness.

Dr. Blagosklonny is eager to share his views and findings, and he does so in his teaching and as the editor of an online newsletter called Oncotarget. His message is that all should learn as much as possible and stay current so that everyone understands how to get the best treatment available. The newsletter contains articles relevant to the field of oncology and the latest methods being used to support human longevity. Rapamycin studies have also been published, with notes relating to detailed findings and next steps.

Will Dr. Mikhail Blagosklonny find a way to increase our life span? If he does not, it certainly won’t be for lack of trying. He is passionate about being able to do so and about how Rapamycin will contribute to these efforts. His mission is to find less invasive, more affordable, and more accessible ways to eliminate the threats to life. He believes we can live longer and be healthier. Clearly more research is needed but all signs point to the fact that he will continue to search until his hypothesis is confirmed. It seems hard to bet against him.

LinkedIn: https://www.linkedin.com/in/mikhail-blagosklonny-91abb531/